Adare

Adare

Adare

Description

The entity profile has not yet been completed.

This entity is yours?
Sign in to update information and position your organization seamlessly within the European bioproduction Value Chain. Benefit from the geolocated map to showcase your expertise, projects, and initiatives. Boost your visibility and make meaningful connections within the ecosystem. Sign in

Adare

Address

Bornago, Lombardy, Italy

Contact

Online form

Description

The entity profile has not yet been completed.

This entity is yours?
Sign in to update information and position your organization seamlessly within the European bioproduction Value Chain. Benefit from the geolocated map to showcase your expertise, projects, and initiatives. Boost your visibility and make meaningful connections within the ecosystem.

Matchmaking

Connect with Adare

Position on the value chain

With the ultimate aim to create a European alliance for bioproduction in Europe, organisations have joined forces with COBIOE. Discover who are our associates.

Bio-resources and biobanking
  • Cells, tissues and humanized xeno-organs
  • Biosamples
  • Viral, phage or bacterial specimen
Identification of biotherapies
  • Target identification
  • Target validation
  • Screening
Drug design
  • Drug assessment
  • Drug engineering
  • In vitro preclinical studies
Clinical validation
  • Clinical trials
  • In vivo preclinical validation
  • Pre-industrial scale production
Production
  • Upstream processes
  • Downstream processes
  • Quality control
Market access
  • CE mark / market authorisation
  • Payment / Reimbursement
  • Care pathways

Adare last news

01/04/2024

Industry Experts Weigh In On Oral Solid Dosage | Contract Pharma

[...] Oral solid dosage (OSD) products have been around since the mid 1800s and still remain the largest category of pharmaceuticals manufactured today—and the most common dose form physicians prescribe for a variety of indications. Reasons oral solids remain dominan [...]

14/03/2024

An API producer's $250M expansion; Noramco launches US API supply; A packaging company's 47% sales jump

Welcome to Endpoints News ' manufacturing briefs, where we bring you essential updates on new builds, collaborations, recalls and more. API producer Bright Green is undergoing a $250 million expansion of its facility in Grants, NM, it said on Tuesday. The company is getting a $60 million loan to support the expansion from an unnamed backer. API manufacturer Noramco said on Thursday that it's launching the Noramco Group to improve supply of APIs and drug production in North America. The Noramco Group will be a collection of its subsidiaries Purisys, Noramco and the CDMO Halo Pharma. It will provide clinical and commercial services for API supply and drug production. "The current crisis, primarily driven by lack of reliable foreign supply, limited domestic manufacturing capacity for APIs and drug products, and logistical bottlenecks, has led to unprecedented challenges in ensuring the availability of essential medications," the company said in the press release. Packaging manufacturer Bormioli Pharma announced a 47% jump in sales in North America for 2023. The company said on Tuesday this increase was due to expanded capacity and its "rapidly evolving infrastructure." Fujifilm Diosynth said it has appointed Richard McAvoy as its new chief financial officer, starting in April. McAvoy previously worked as the site head of Fujifilm's Holly Springs, NC, facility, according to a Monday release. CDMO Chime Biologics will manufacture Domain Therapeutics' monoclonal antibody candidate DT-7012 for solid tumors as it enters a Phase I trial in early 2025, according to a Tuesday release. Charles River announced its collaboration with Navega Therapeutics to make the company's adeno-associated virus (AAV) based gene therapy, NT-001 for Phase I clinical trials. NT-001 is being investigated for treatment against chronic pain conditions associated with rare diseases such as small fiber neuropathy and primary erythromelalgia, a Wednesday release states. Anocca and EmendoBio have entered a licensing agreement , with Anocca getting access to EmendoBio's OMNI-A4 nuclease to manufacture its pipeline of T cell receptor-engineered T cell therapies for solid cancers, as per a Thursday announcement. Autolus Therapeutics has received a Manufacturer's Importation Authorisation (MIA) from the UK's MHRA for its manufacturing site in Stevenage, UK, the company said Tuesday. CDMO Alcami announced a new partnership with Tanvex CDMO on Tuesday, to offer services in bulk drug substance production. Oral dose CDMO Adare Pharma Solutions is expanding its Pessano facility in Milan, Italy, to house a new granulation suite which will become operational in the third quarter of 2024, the company said on Tuesday.

13/03/2024

Adare to Expand Oral Dose Capabilities in Italy

US CDMO Adare Pharma Solutions is to add a high-shear mixer granulator at its Pessano, Italy facility, to complement existing fluid bed capabilities. The new mixer can provide wet granulation using either aqueous or organic-based solutions.